thyroid eye disease Horizon Pharma
Horizon Pharma completes enrolment in Phase lll study of teprotumumab
Horizon Pharma has completed patient enrolment for the Phase lll OPTIC trial of teprotumumab to treat patients with moderate-to-severe active…
